First in-human results
In 2011 our research group performed the first in-human fluorescence study concerning intraoperative staining of ovarian cancer.
Read more
In 2011 our research group performed the first in-human fluorescence study concerning intraoperative staining of ovarian cancer.
Read moreThe TRACT-I was the first study that utilized NIR spectroscopy in rectal cancer patients using Bevacizumab-IRDye800CW.
Read moreIn 2014 the first study started using systemic and topical administration of a fluorescence-labelled antibody against vascular endothelial growth factor (VEGF) utilizing a NIR infrared camera system.
Read moreStart of ICON study; the first Head and Neck Cancer study at OMIG. The ICON study is a clinical trial for the intraoperative assessment of tumor margins during surgical treatment using cetuximab-IRDye800CW
Read moreThe Thyroid Cancer Target study is a dual study. The first part started in 2018, using EMI-137 in targeting thyroid cancer. The second part started in 2021, utilizing Bevacizumab-IRDye800CW.
Read moreThe VISION study is the first study that focussed on IBD pathology. In this study Vedolizumab-800CW is utilized to identify inflamed gut mucosa using near-infrared fluorescence molecular endoscopy (NIR-FME), spectroscopy and confocal laser endomicroscopy (CLE).
Read more